CORCEPT THERAPEUTICS INC (CORT) Revenue, Margins & Financial Statements
CORCEPT THERAPEUTICS INC (CORT) reported $761.41M in revenue over the most recent fiscal year on record, up 12.8% year over year. Growth has been stable, a +17.2% compound annual rate over the last 7 years on record. Sales are growing but profit is not, worth checking why costs are outrunning revenue. Operating margin is the lowest of the last 8 years on record. Free cash flow ran 142% of net income in the latest year, cash generation is outpacing reported profit, a sign of solid earnings quality. The balance sheet holds $372.15M more in cash & investments than debt. Share count has been roughly stable over the past year.
CORCEPT THERAPEUTICS INC's revenue for the fiscal year ended Dec 2025 was $761.41M, an increase of +12.8% compared to the prior year. Is growth accelerating, stable, slowing, or contracting? See the quarterly beat/miss history →
| Fiscal Year Ended | Revenue Growth |
|---|---|
| Dec 2025 | +12.8% |
| Dec 2024 | +39.9% |
| Dec 2023 | +20.0% |
| Dec 2022 | +9.8% |
| Dec 2021 | +3.4% |
| Dec 2020 | +15.5% |
| Dec 2019 | +22.0% |
"Accelerating" / "Slowing" means each of the last 3 years' growth rates moved consistently in that direction, not a subjective call.
Year-over-year growth by quarter, each quarter compared to the same quarter one year earlier, which avoids the seasonal noise of comparing sequential quarters. CORCEPT THERAPEUTICS INC's most recent quarter grew +31.7% year-over-year, faster than the quarter before it.
| Quarter Ended | Revenue | YoY Growth |
|---|---|---|
| Jun 2026 | $256.15M | +31.7% |
| Mar 2026 | $164.90M | +4.9% |
| Dec 2025 (derived) | $202.13M | +11.1% |
| Sep 2025 | $207.64M | +13.7% |
| Jun 2025 | $194.43M | +18.7% |
| Mar 2025 | $157.21M | +7.1% |
| Dec 2024 (derived) | $181.89M | +34.3% |
| Sep 2024 | $182.55M | +47.7% |
Net income grew +22.3% year-over-year in the same quarter.
Sales are growing but profit is not, worth checking why costs are outrunning revenue.
Compared against 7 other Healthcare stocks tracked on this site, not the whole market, and small enough that this is directional context, not a definitive benchmark.
EPS -33.3% year over year. A rough breakdown of what drove it (approximate, since EPS is roughly net income divided by share count):
Accounting profit is not the same as cash in the bank. Here's how CORT converts revenue into real cash.
How CORT deployed cash in the most recent year, across its actual cash-flow-statement uses.
Objective, rule-based checks against the figures above, not a subjective rating.
| Fiscal Year Ended | Revenue Growth | Margin Change | FCF Growth |
|---|---|---|---|
| Dec 2025 | +12.8% | -14.4pp | -27.7% |
| Dec 2024 | +39.9% | -2.0pp | +55.0% |
| Dec 2023 | +20.0% | -5.8pp | +5.5% |
| Dec 2022 | +9.8% | -6.0pp | -28.4% |
| Dec 2021 | +3.4% | -2.2pp | +11.1% |
| Dec 2020 | +15.5% | -0.2pp | +11.6% |
| Dec 2019 | +22.0% | +0.8pp | +17.0% |
Is CORT's revenue growing?
CORCEPT THERAPEUTICS INC's revenue growth has been stable, at +12.8% in the most recent year on record. Over the last 7 years, revenue has compounded at roughly +17.2% annually.
Is CORT's profit growing faster than its revenue?
Sales are growing but profit is not, worth checking why costs are outrunning revenue.
Are CORT's profit margins improving or declining?
Operating margin has compressed for 6 straight years on record. It is currently the lowest of the last 8 years.
Is CORT's reported profit backed by real cash?
Operating cash flow ran +142% of net income, and free cash flow ran +142% of net income, in the most recent year. Cash generation is outpacing reported accounting profit.
Does CORT have more cash than debt?
Yes, CORT holds $372.15M more in cash & short-term investments than its total debt.
Is CORT diluting shareholders or buying back stock?
CORT's share count has been roughly flat over the past year.
What are the biggest financial red flags for CORT right now?
Gross margin has declined for 3 straight years on record. Operating margin has compressed for 6 straight years on record.
Every line item as reported, with the annual/quarterly toggle and ratio table.
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $761.41M | $675.04M | $482.38M | $401.86M | $365.98M |
| Cost of Revenue | $12.98M | $10.88M | $6.48M | $5.38M | $5.28M |
| Gross Profit | $748.43M | $664.16M | $475.89M | $396.47M | $360.70M |
| Research & Development | $254.91M | $246.89M | $184.35M | $130.99M | $113.86M |
| Selling, General & Administrative | $448.73M | $280.32M | $184.26M | $152.85M | $122.36M |
| Total Operating Expenses | $716.61M | $538.09M | $375.09M | $289.22M | $241.50M |
| Operating Income | $44.80M | $136.95M | $107.28M | $112.63M | $124.48M |
| Nonoperating Income (Expense) | $21.67M | $24.54M | $17.27M | $3.56M | $529.0K |
| Pretax Income | $66.46M | $161.49M | $124.56M | $116.19M | $125.01M |
| Income Tax Expense | -$33.19M | $20.28M | $18.42M | $14.77M | $12.49M |
| Net Income | $99.65M | $141.21M | $106.14M | $101.42M | $112.51M |
| EPS (Basic) | $0.95 | $1.35 | $1.02 | $0.95 | $0.97 |
| EPS (Diluted) | $0.82 | $1.23 | $0.94 | $0.87 | $0.89 |
| Weighted Avg Shares (Basic) | 103.86M | 103.23M | 103.56M | 106.79M | 115.65M |
| Weighted Avg Shares (Diluted) | 119.99M | 113.48M | 111.74M | 115.97M | 125.96M |
Sourced from SEC filings (10-K / 10-Q). Figures not separately reported by the company are shown as —, not estimated. Quarterly "derived Q4" values are calculated as the full fiscal year total minus the three reported quarters.
Computed from the annual figures above, most recent first.
| Ratio | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 98.3% | 98.4% | 98.7% | 98.7% | 98.6% | 98.4% | 98.2% | 97.9% |
| Operating Margin | 5.9% | 20.3% | 22.2% | 28.0% | 34.0% | 36.2% | 36.4% | 35.6% |
| Net Margin | 13.1% | 20.9% | 22.0% | 25.2% | 30.7% | 30.0% | 30.7% | 30.0% |
| Return on Equity | 15.4% | 20.8% | 20.9% | 20.2% | 29.9% | 20.3% | 25.4% | 27.3% |
| Current Ratio | 2.92 | 3.35 | 4.39 | 6.89 | 5.60 | 10.07 | 7.91 | 6.66 |
| Debt / Equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | $141.78M | $196.12M | $126.54M | $119.91M | $167.42M | $150.73M | $135.03M | $115.37M |